TARDBP and amyotrophic lateral sclerosis: ALS and FTD patients without the risk SNPs also have some cryptic splicing events (because they also have TDP‐43 pathology), so it is likely that therapeutic reduction of UNC13A cryptic splicing will be beneficial in these patients as well.